Researchers: Dr. Todd Cooper and Dr. Adam Lamble
We have now successfully received paired sequencing and high throughput drug screen results on our first patients. These were obtained within a clinically meaningful timeframe and we were able to convene our first precision medicine tumor board to review results and provide patient specific treatment recommendations. These recommendations were based on the patient’s mutational profile and drug sensitivity results. We are going to continue spreading awareness and anticipate most providers/patients will be interested in participating in the study. We are excited about the prospect of expanding this trial to external institutions and continue to engage with our industry sponsor regarding this potential opportunity.
You must be logged in to post a comment.
Sign up to comment in the forums, on posts, and receive our newsletters.